We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

General Biologicals Corporation (GBC)

General Biologicals Corp. (GBC), founded in 1984, is the industry-leading in-vitro diagnostic device manufacturer in ... read more Featured Products: More products

Download Mobile App





General Biologicals Displays CLIA and Molecular Diagnostic Solutions at WHX Labs Dubai

By LabMedica International staff writers
Posted on 12 Feb 2026

At WHX Labs Dubai 2026, General Biologicals Corporation (GBC) is presenting its latest in vitro diagnostics (IVD) technologies and integrated laboratory solutions at Booth SA. More...

D50, February 10–13 at the Dubai World Trade Centre.

In molecular diagnostics, the company is demonstrating the AIO M160 fully automated system, which integrates nucleic acid extraction, amplification, and detection within a single platform. The system is designed to deliver a sample-to-result workflow, reducing manual intervention while improving operational efficiency. The compact system is built for efficiency, processing up to 16 samples simultaneously with a total turnaround time of under 2.5 hours. It features a high multiplexing capability with five qPCR channels, allowing for both qualitative and quantitative results from various sample types like whole blood, plasma, and tissue.

GBC is also showcasing its chemiluminescence immunoassay (CLIA) system, developed for laboratories of varying sizes. The platform includes the GBC CL i-120 CLIA System, an automated analyzer that optimizes workflows for protein and antibody detection. This technology is applied across a wide range of health targets, including thyroid function, tumor markers, and infectious disease screening.

Among the other featured technologies is the CellBio™ CTC circulating tumor cell detection platform, a non-invasive system designed to isolate circulating tumor cells (CTCs) from blood samples. The platform supports multi-level molecular analysis of DNA, RNA, and proteins, enabling applications in early cancer detection, therapy monitoring, and precision oncology research. The product lineup includes the CellBio™ a2000 for standard workflows and the CellBio™ FX10 for high-throughput laboratory environments. The platform preserves intact cell morphology, allowing for a wide range of downstream analyses including immunostaining, FISH, and NGS.

Live product demonstrations are being conducted at the booth, where attendees can learn more about the company’s technologies and discuss implementation and partnership opportunities.

Related Links:
General Biologicals Corporation


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
New
Gastrointestinal Panel
Xpert® GI Panel
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: WashU Medicine researchers found that dozens of blood proteins shift during Alzheimer’s treatment and may help monitor the effects of the medication. (Image Credit: Matt Miller/WashU Medicine)

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Molecular Diagnostics

view channel
Image: University of Florida scientists Hugh Fan, Ph.D., and John Lednicky, Ph.D., led the development of a cost-effective, accurate handheld device capable of simultaneously testing for seven different mosquito-borne viruses. (Image Credit: UF Health photo by Hannah Clark)

Portable Test Differentiates Seven Mosquito-Borne Viruses at Point of Care

Mosquito-borne viral illnesses can present with overlapping symptoms such as fever, joint pain, fatigue, and rash, making them difficult to distinguish without laboratory testing. In these settings, clinicians... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.